Announcement PDF ASX Announcement 24 July 2023 Microba to Present at 17th Bioshares Biotech Summit Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”) is pleased to announce that Chief Executive Officer, Dr Luke Reid and SVP, Therapeutics Prof. Trent Munro will present at the 17th Bioshares Biotech Summit in Hobart, Australia at 4.35pm AEST today. A copy of the Bioshares Biotech Summit presentation is attached below. This announcement has been authorised for release by the Chairman and Chief Executive Officer. For further information, please contact: Dr Luke Reid Chief Executive Officer E: Luke.Reid@microba.com Simon Hinsley Investor / Media Relations E: simon@nwrcommunications.com.au T: +61 401 809 653 About Microba Life Sciences Limited Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions. For more information visit: www.microba.com Microba encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group. Microba Life Sciences Ltd ABN 82 617 096 652 Level 10, 324 Queen Street, Brisbane QLD 4000 Australia T: 1300 974 621 E: investor@microba.com W: microba.com PRECISION MICROBIOME THERAPEUTICS 24 July 2023 Disclaimer This presentation (Presentation) has been prepared by Microba Life Sciences Limited (Microba). Summary information - This Presentation contains summary information about Microba and its activities which is current only as at the date of release of this Presentation. Microba may in its absolute discretion, but without being under any obligation to do so, update or supplement this Presentation. The information in this Presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in Microba or that would be required in a prospectus or other disclosure document prepared in accordance with the requirements of the Corporations Act 2001 (Cth) (Corporations Act). Industry and market data – In this Presentation, Microba refers to certain market, industry, and statistical data used in connection with this Presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither Microba nor its representatives have independently verified any such data and no representation or warranty, express or implied, is made as to its fairness, accuracy, correctness, completeness or adequacy. Some data is also based on the good faith estimates of Microba, which are derived its reviews of internal sources as well as the independent sources described above. Not an offer - This Presentation is not a prospectus or other disclosure document under the Corporations Act and will not be lodged with the Australian Securities and Investments Commission. This Presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. The distribution of this Presentation (including electronically) outside Australia may be restricted by law. If you come into possession of this Presentation, you should observe such restrictions and should seek your own advice. Any non-compliance with these restrictions may contravene applicable securities laws. Not investment or medical advice - The information contained in this Presentation is not investment, financial product advice, medical advice or any medical recommendation or recommendation to acquire Shares. This Presentation has been prepared without taking into account your investment objectives, financial situation, medical or any other particular needs This Presentation does not and will not form any part of any contract for the acquisition of shares. Each recipient of this Presentation should make its own enquiries and investigations regarding all information in this Presentation. Before making an investment decision, you should consider whether it is a suitable investment for you in light of your own investment objectives, financial situation and particular needs and having regard to the merits or risks involved. Independent financial advice is recommended. Future performance - This Presentation contains forward looking statements. Forward-looking statements generally relate to current expectations, hopes, beliefs, intentions, strategies or productions about future events or Microba's future financial or operating performance. For example, statements regarding anticipated growth in the industry in which Microba operates and anticipated growth in demand for Microba's products and services, projections of Microba's future financial results and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "pro forma", "may", "should", "could", "might", "plan", "possible", "project", "strive", "budget", "forecast", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forwardlooking. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance and may involve known and unknown risks, uncertainties and other factors, many of which are outside the control of Microba. You are cautioned not to place undue reliance on any forward looking statement. Forward looking statements in this Presentation are based on assumptions and contingencies which are subject to change without notice. Actual results, performance or achievements may vary materially from any forward looking statements and the assumptions on which statements are based. The forward looking statements in this Presentation are based on information available to Microba as at the date of this Presentation and nothing in this Presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. Except as required by law or regulation, Microba undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise. Financial data – All dollar values in Australian dollars (A$ or $) unless otherwise stated. Recipients should note that this Presentation contains historical and pro-forma financial information. Any financial information provided in this Presentation is for illustrative purposes only and is not represented as being indicative of Microba’s views on its future financial condition and/or performance. Trademarks – This Presentation may contain trademarks, trade names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, some of the trademarks, trade names and copyrights referred to in this Presentation may be listed without the © or ® symbols, but Microba asserts, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, trade names and copyright. Disclaimer - Except for any statutory liability which cannot be excluded, Microba, its related bodies corporate and their respective officers, employees and advisers expressly disclaim all liability (including negligence) for any direct or indirect loss or damage which may be suffered by any person in relation to, and take no responsibility for, any information in this Presentation or any error or omission therefrom, and make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of this Presentation. 2 up to 95% coverage Other Technology Microba Technology up to 34x more accurate Published in 1 Calculated by analysing more than 10k samples across Microba’s databank 2 Microba achieves 6-34x lower false discovery rate than academic competitors Parks, Donovan H., et al. "Evaluation of the Microba Community Profiler for Taxonomic Profiling of Metagenomic Datasets From the Human Gut Microbiome." Frontiers in microbiology 12 (2021). 3 Services Databank Proprietary databank Data Testing Health Data Therapeutics Insights Novel Therapies Biome Data Microba provides testing and data analysis for a fee to clinicians, consumers and research customers Driving discovery of novel therapeutic leads Data-driven product platform developing novel live biotherapeutics Two core business segments driven by a proprietary databank 4 Company Snapshot Continuous YoY revenue growth over 5 years of operations Partnerships with market leaders incl. Sonic Healthcare (ASX: SHL), Ginkgo Bioworks (NYSE: DNA), SYNLAB (GR:SYAB) + more Large, unique, proprietary microbiome databank 3 key therapeutic programs with lead IBD drug candidate in Phase I trial World-leading technology in the emerging and rapidly growing US$4.89 billion microbiome sector1 Globally leading microbiome expertise complemented by drug discovery experts including Prof. Ian Frazer 5 Microbiome testing services business • Continued YoY revenue growth • Leading bench of global partners provides access to 35 countries with 13 now operational • At the forefront of rapidly emerging microbiome testing market • Opportunity to disrupt diagnostic markets including infectious disease testing Driving global revenues and databank growth Contracted partner/s operational Access to this country through existing distribution partner network 6 Precision Microbiome Therapeutics Novel Pipeline of Microbiome Therapies Precision microbiome analysis platform delivering unparalleled accuracy, coverage & depth.  Potent and novel biology mediated by Live Biotherapeutic strategy  Data driven discovery platform utilising one of the worlds most advanced & highly curated microbiome datasets.  Excellent safety profile  Next generation approach to microbiome drug development identifying and isolating single keystone species to develop Live Biotherapeutics.  Microba Partners  Scalable GMP manufacturing for high dose oral delivery Experienced Leadership Luke Reid CEO Trent Munro SVP Therapeutics Prof Ian Frazer Prof Gene Tyson Prof Phil Hugenholtz Director & MAB Chair Co-Founder Co-Founder 7 Evolution of Microbiome based Therapeutics 1 First Generation Fecal Doner Derived 2 Second Generation 3 Next Generation Bacterial Consortia FDA approval Nov 30 2022 Faeacal doner derived enema drug product Vedanta Biosciences Vedanta Biosciences Raises $106.5M in Funding FDA approval April 27 2023 Faeacal doner derived oral capsule drug product SER-155 Phase Ib showing engraftment reduction in pathogens Single Strain & Small Molecule MAP 315 Phase I H1 FY2024 8 Human data driven insights Microbiome Databank OA NAFLD RA IBS Asthma Eczema Health Data IBD PS T2D Biome Data GORD Neurological Disorders and Mental Health Lupus IO Obesity CVD Precision Microbiome Therapeutics 9 Therapeutic Pipeline Program Discovery R&D Preclinical Phase 1 Phase 2 Phase 3 Development Partners Multiple IBD MAP 315 Immuno-oncology * Multiple Multiple Autoimmunne Multiple Multiple * Phase I clinical trial commenced first dosing in June 2023, result expected to be available in December 2023 10 Inflammatory Bowel Disease 11 Data-driven platform driving discovery of novel biotherapeutics * * * * * Databank numbers at the time the IBD discovery program was executed 12 IBD Program: Clinical data-driven discovery Lead candidate MAP 315: Microba’s technology allows clear distinction from closely related species • Identification enabled by Microba’s precision microbiome measurements MAP 315 • A previously uncultivated, uncharacterized species • Rationally discovered and replicated in human datasets • Clearly stands out from other species Phylogenetic tree of all bacterial species within the same family as MAP 315 Prevalence in: Prevalence (%) 13 IBD Program: MAP 315 Biology pathology in induced 1 Improved colitis mouse models barrier integrity by modulating 2 Supports gut epithelial cell tight junctions ns **** epithelial cell migration & suppresses 3 Promotes cytokine driven inflammatory response MAP 315 promotes migration of epithelial cells & wound closure MAP 315 suppress IL-6 mediated activation of STAT3 area [microns2] *** ns IFNγ (100 ng/mL) Histopathological score (pg/mg feces) Lipocalin DSS **** - + + Score * + DSS - + + + MAP 315 ameliorates IFNγ driven changes in cytokine, chemokine and tight junction protein gene expression MAP 315 induces cytokine production in human peripheral blood mononuclear cells in line with driving an antiinflammatory effect 14 MAP 315 at the forefront of live biotherapeutics a new potential major class of therapeutics • MAP 315 has the potential to provide novel, potent therapeutic benefit to UC patients through addressing a key gap in existing care – epithelial and mucosal healing • MAP 315 is a clinical stage, orally delivered, single strain live biotherapeutic differentiated from donor derived or microbiome cocktail approaches simplifying CMC and regulatory pathway Inflammatory Bowel Disease $10B+ Ulcerative Colitis & Crohn’s Disease 1 Favourable safety profile All patients regardless of line of therapy Bringing the promise of precision microbiome therapy to IBD Expanded Inflammatory Disease Opportunity $50B+ Large market for additional Inflammation-Driven Indications 2 Fibrosis Atopic Dermatitis/Psoriasis 1 https://www.nature.com/articles/d41573-021-00194-5 , https://www.alliedmarketresearch.com/ulcerative-colitis-market 2 https://www.fiercepharma.com/pharma/analysts-humira-not-peak-and-immunology-market-only-getting-bigger, https://www.fnfresearch.com/news/global-rheumatoid-arthritis-drugs-market Rheumatoid Arthritis 15 Oncology 16 Advancing response to immune checkpoint inhibitors through the gut microbiome Between 42% - 70% of patients do not respond to ICI therapy1,2 Modulation of gut microbiome using fecal microbiome transplant improved ICI response in Phase I and II studies4,5 Over 30 published studies support the influence of the gut microbiome on ICI response 1Leonardi et al. (2020). International Journal of Oncology. DOI: 10.3892/ijo.2020.5088 4Baruch et al. (2020). Science. DOI: 10.1126/science.abb5920 3Larkin et al. (2019). New England Journal of Medicine. DOI: 10.1056/NEJMoa1910836 * Immune-related adverse events 2Wolchok et al. (2017). New England Journal of Medicine. DOI: 10.1056/NEJMoa1709684 5Davar et al. (2021). Science. DOI: 10.1126/science.abf3363 17 Oncology Program: Discovery & POC 1 2 Human clinical data driven lead candidate discovery Proof of concept achieved in immune checkpoint inhibitor (ICI) refractive mouse model Feature importance (SHAP) Positive animal efficacy data has been generated for Microba’s immuno-oncology therapeutic leads. Meta-analysis of multiple datasets using Microba’s high-resolution technology identifies multiple species not previously found to be associated with treatment response. A significant reduction in tumour size was observed in combination with immune checkpoint inhibitor (ICI) treatment in a mouse model of melanoma. Strongly associated with treatment response Developing breakthrough microbiome-derived cancer immunotherapy Spencer et al., Science 374, 1632–1640 (2021), Lee at al., Nat Med 28, 535–544 (2022) Frankel et al., Neoplasia (2017) 19, 848–855, McCulloch, et al.,. Nat Med 28, 545–556 (2022). 18 Autoimmune Disease 19 Autoimmune: Drug Discovery Program Human Data Guided Discovery Engine Ginkgo Anaerobic Foundry Drug Discovery Program for Autoimmune Disease Microba Donor Biobank Microba and Ginkgo Bioworks have established a Microbiome Drug Discovery Program targeting Autoimmune Diseases including Psoriatic Arthritis, Autoimmune Liver Disease and Lupus. 20 Autoimmune Program: Significant hit rate and potency observed in primary screens Immune Suppression Activity Reduced Cell Migration Activity Wound c onflue nc y (%) 0 25 50 75 100 75 50 25 10% Mic roba Le a d s tra ins Inte rfe ron-ɣ re le a s e (%) Media Mic roba Le a d s tra ins Im m une s uppres s ion a s s a y da ta in PBMCs s howing s uppres s ion of IFNγ production IL-1β re le a s e (%) 100 0 Reduced Inflammasome Activity Mic roba Le a d s tra ins Fibrobla s t Migra tion As s a y da ta s howing a ctivity releva nt for fibrotic rem odeling Infla m ma s ome a ctiva tion a s s a y in THP1 cells s howing reduction in IL-1 β 21 Some recent IBD and microbiome deals Licensee / Acquiror Licensor / Target Date Type Deal size Indication / clinical stage Apr 2023 (pending) Acquisition Total deal size: US$10.8b Ulcerative Colitis (phase 2) Crohn’s disease (phase 2A) Autoimmune diseases (phase I or pre clinical) July 2022 R&D collaboration and license agreement Total deal size: Undisclosed Upfront: €40m Sales / regulatory milestones: Undisclosed Food allergies and IBD (pre clinical) Mar 2022 Acquisition Total deal size: US$6.7b Ulcerative Colitis (phase 3), Crohn’s disease (phase2/3), Atopic dermatitis (phase 2 complete) Nov 2021 R&D collaboration and license agreement Total deal size: US$605m Upfront: US$15m Additional payments: US$590m IBD (Discovery) Jul 2021 Licensing agreement in US/Canada Total deal size: US$525m Upfront: US$175m Sales / regulatory milestones: Up to US$225m Recurrent Clostridioides difficile infection (Phase 3) https://www.merck.com/news/merck-strengthens-immunology-pipeline-with-acquisition-of-prometheus-biosciences-inc/ https://www.enterome.com/news-events/enterome-signs-major-strategic-rd-collaboration-with-nestle-health-science-to-develop-and-commercialize-new-allermimics-and-endomimics-immunotherapies-for-food-allergies-and-inflamm/ https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-arena-pharmaceuticals http://novomebio.com/wp-content/uploads/2021/11/Novome-and-Genentech-Enter-into-Strategic-Collaboration.pdf https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-nestle-health-science-announce-ser-109-co 23 Upcoming Milestones for 2023 2023 JAN – MAR 2023 APR - JUN 2023 JUL - DEC Services Services Services Services Therapeutics - IBD MAP 315 program Services Therapeutics - IBD MAP 315 program Therapeutics - IBD MAP 315 program Therapeutics - IBD MAP 315 program Therapeutics - IBD MAP 315 program Therapeutics - IBD MAP 315 program Therapeutics - IBD MAP 315 program New healthcare product full launch New international distribution deals Phase I HREC Submission FDA Pre-IND meeting outcome New international distribution deals HREC Approval for Phase I trial GMP manufacture complete Phase I Phase I trial commencement New country expansion First Sonic partners operational Phase I participant dosing complete Phase I complete Therapeutics - IO Program Therapeutics – IO Program Therapeutics – Autoimmune Program Therapeutics - Autoimmune Program Pre-clinical results First in vitro screening results Immunological pre-clinical results Stage 1 activity screening complete 24 CONTACT Prof. Trent Munro SVP, Therapeutics trent.munro@microba.com Dr Luke Reid Chief Executive Officer luke.reid@microba.com